Tansey, K. E., Rucker, J. J. H., Kavanagh, D. H., Guipponi, M., Perroud, N., Bondolfi, G., Domenici, E., Evans, D. M., Hauser, J., Henigsberg, N., Jerman, B., Maier, W., Mors, O., O'Donovan, M., Peters, T. J., Placentino, A., Rietschel, M., Souery, D., Aitchison, K. J., ... Uher, R. (2014). Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics Journal, 14(4), 395-399. https://doi.org/10.1038/tpj.2013.51
Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. / Tansey, K. E.; Rucker, J. J.H.; Kavanagh, D. H. 等.
在:
Pharmacogenomics Journal, 卷 14, 号码 4, 08.2014, 页码 395-399.
科研成果: 期刊稿件 › 文章 › 同行评审
Tansey, KE, Rucker, JJH, Kavanagh, DH, Guipponi, M, Perroud, N, Bondolfi, G, Domenici, E, Evans, DM, Hauser, J, Henigsberg, N, Jerman, B, Maier, W, Mors, O, O'Donovan, M, Peters, TJ, Placentino, A, Rietschel, M, Souery, D, Aitchison, KJ, Craig, I, Farmer, A, Wendland, JR, Malafosse, A, Lewis, G, Kapur, S, McGuffin, P & Uher, R 2014, 'Copy number variants and therapeutic response to antidepressant medication in major depressive disorder', Pharmacogenomics Journal, 卷 14, 号码 4, 页码 395-399. https://doi.org/10.1038/tpj.2013.51
Tansey KE, Rucker JJH, Kavanagh DH, Guipponi M, Perroud N, Bondolfi G 等. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics Journal. 2014 8月;14(4):395-399. doi: 10.1038/tpj.2013.51
Tansey, K. E. ; Rucker, J. J.H. ; Kavanagh, D. H. 等. / Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. 在: Pharmacogenomics Journal. 2014 ; 卷 14, 号码 4. 页码 395-399.
@article{83bbf7d0e862468badd3156349356cbd,
title = "Copy number variants and therapeutic response to antidepressant medication in major depressive disorder",
author = "Tansey, {K. E.} and Rucker, {J. J.H.} and Kavanagh, {D. H.} and M. Guipponi and N. Perroud and G. Bondolfi and E. Domenici and Evans, {D. M.} and J. Hauser and N. Henigsberg and B. Jerman and W. Maier and O. Mors and M. O'Donovan and Peters, {T. J.} and A. Placentino and M. Rietschel and D. Souery and Aitchison, {K. J.} and I. Craig and A. Farmer and Wendland, {J. R.} and A. Malafosse and G. Lewis and S. Kapur and P. McGuffin and R. Uher",
note = "Funding Information: The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under Grant agreement no. 115008 of which resources are composed of European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and financial contribution from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013). EFPIA members Pfizer, Glaxo Smith Kline and F. Hoffmann La-Roche have contributed work and samples to the project presented here. GENDEP was funded by the European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. Lundbeck provided nortriptyline and escitalopram for the GENDEP study. GlaxoSmithKline and the UK National Institute for Health Research of the Department of Health contributed to the funding of the sample collection at the Institute of Psychiatry, London. GENDEP genotyping was funded by a joint grant from the UK Medical Research Council (MRC, UK) and GlaxoSmithKline (G0701420). GenPod was funded by the Medical Research Council (MRC, UK) and supported by the Mental Health Research Network. GODS study was partly supported by external funding provided by the Swiss branches of the following pharmaceutical companies: GlaxoSmithKline, Wyeth-Lederle, Bristol-Myers-Squibb and Sanofi Aventis. RU is supported by the Canada Research Chair program (http:// www.chairs-chaires.gc.ca/). JR was supported by a fellowship from the Wellcome Trust (086635).",
year = "2014",
month = aug,
doi = "10.1038/tpj.2013.51",
language = "English",
volume = "14",
pages = "395--399",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "4",
}
TY - JOUR
T1 - Copy number variants and therapeutic response to antidepressant medication in major depressive disorder
AU - Tansey, K. E.
AU - Rucker, J. J.H.
AU - Kavanagh, D. H.
AU - Guipponi, M.
AU - Perroud, N.
AU - Bondolfi, G.
AU - Domenici, E.
AU - Evans, D. M.
AU - Hauser, J.
AU - Henigsberg, N.
AU - Jerman, B.
AU - Maier, W.
AU - Mors, O.
AU - O'Donovan, M.
AU - Peters, T. J.
AU - Placentino, A.
AU - Rietschel, M.
AU - Souery, D.
AU - Aitchison, K. J.
AU - Craig, I.
AU - Farmer, A.
AU - Wendland, J. R.
AU - Malafosse, A.
AU - Lewis, G.
AU - Kapur, S.
AU - McGuffin, P.
AU - Uher, R.
N1 - Funding Information:
The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under Grant agreement no. 115008 of which resources are composed of European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013). EFPIA members Pfizer, Glaxo Smith Kline and F. Hoffmann La-Roche have contributed work and samples to the project presented here. GENDEP was funded by the European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. Lundbeck provided nortriptyline and escitalopram for the GENDEP study. GlaxoSmithKline and the UK National Institute for Health Research of the Department of Health contributed to the funding of the sample collection at the Institute of Psychiatry, London. GENDEP genotyping was funded by a joint grant from the UK Medical Research Council (MRC, UK) and GlaxoSmithKline (G0701420). GenPod was funded by the Medical Research Council (MRC, UK) and supported by the Mental Health Research Network. GODS study was partly supported by external funding provided by the Swiss branches of the following pharmaceutical companies: GlaxoSmithKline, Wyeth-Lederle, Bristol-Myers-Squibb and Sanofi Aventis. RU is supported by the Canada Research Chair program (http:// www.chairs-chaires.gc.ca/). JR was supported by a fellowship from the Wellcome Trust (086635).
PY - 2014/8
Y1 - 2014/8
UR - http://www.scopus.com/inward/record.url?scp=84904960520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904960520&partnerID=8YFLogxK
U2 - 10.1038/tpj.2013.51
DO - 10.1038/tpj.2013.51
M3 - Article
C2 - 24445990
AN - SCOPUS:84904960520
SN - 1470-269X
VL - 14
SP - 395
EP - 399
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
IS - 4
ER -